AMRX — AMNEAL PHARMACEUTICALS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About AMNEAL PHARMACEUTICALS INC (AMRX)
AMNEAL PHARMACEUTICALS INC (AMRX) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $78M. Across recent filings, tracked investors recorded 5 new positions, 0 increased, 0 reduced, and 1 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in AMRX
How many top investors track AMRX
A small number of top investors own this.
AMRX Ownership Composition
How AMNEAL PHARMACEUTICALS INC is held across tracked investor types, based on reported 13F positions.
- Other93.0%
- Hedge Funds7.0%
Tracked investors reporting AMRX
- Ken GriffinMar 31, 2026Citadel AdvisorsShares619.4KValue$7.7M% Portfolio0.00%
- Izzy EnglanderMar 31, 2026Millennium ManagementShares419.7KValue$5.2M% Portfolio0.00%
- Steve CohenMar 31, 2026Point72 Asset ManagementShares78.1KValue$970.8K% Portfolio0.00%
Recent activity
- $42.3MFeb 17, 2026
- $5.2MMay 15, 2026
- New$7.7MMay 15, 2026
- New$970.8KMay 15, 2026
- Sold$0(-100.00%)Feb 17, 2026
- New$57.6MNov 14, 2025
Frequently asked questions
- How many institutional investors hold AMRX?
- 3 tracked institutional investors disclosed a position in AMRX (AMNEAL PHARMACEUTICALS INC) in their most recent 13F filing.
- Who is the largest institutional holder of AMRX?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in AMRX, valued at $78M.
- Did institutional ownership of AMRX increase or decrease?
- Across recent 13F filings, tracked investors recorded 5 new positions, 0 increased, 0 reduced, and 1 fully exited AMRX.
- Where does this AMRX ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.